Pfizer’s LITFULO Shows Strong Phase 3 Results for Nonsegmental Vitiligo

  • Pfizer’s LITFULO (ritlecitinib) demonstrated significant improvements in facial and total body repigmentation in two Phase 3 trials (TRANQUILLO 2 and TRANQUILLO) for nonsegmental vitiligo.
  • 21.86% of patients on 100 mg LITFULO achieved F-VASI75 compared to 2.40% on placebo; 13.02% achieved T-VASI50 vs. 2.40% on placebo.
  • Pfizer plans to submit these data to regulatory authorities, including the FDA and EMA, for review.
  • The safety profile of LITFULO in NSV was consistent with its established safety profile in alopecia areata, with no new safety signals observed.

Pfizer’s LITFULO represents a potential breakthrough in treating nonsegmental vitiligo, an autoimmune disease with limited systemic treatment options. The positive Phase 3 results position LITFULO as a potential first-in-class oral therapy, addressing a significant unmet need in dermatology. Pfizer’s strategic focus on immune-mediated dermatologic conditions could expand its portfolio beyond alopecia areata, reinforcing its leadership in this therapeutic area.

Regulatory Approval
Whether the FDA and EMA will approve LITFULO for nonsegmental vitiligo based on the Phase 3 trial results.
Market Positioning
How LITFULO will compete in the vitiligo treatment market, given its dual mechanism targeting JAK3 and TEC family kinases.
Commercialization Strategy
The pace at which Pfizer can commercialize LITFULO for vitiligo, leveraging its existing approval for alopecia areata.